Establishment Labs to Present at the 42nd Annual J.P. Morgan Healthcare Conference
29 December 2023 - 12:30AM
Business Wire
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global
medical technology company dedicated to improving women’s health
and wellness, principally in breast aesthetics and reconstruction,
today announced that Juan José Chacón-Quirós, Founder and Chief
Executive Officer, and Raj Denhoy, Chief Financial Officer, will
present at the 42nd Annual J.P. Morgan Healthcare Conference on
Wednesday, January 10, 2024 at 2:15 p.m. Pacific Time.
A live webcast of the presentation will be available on the
Establishment Labs investor relations website at
https://investors.establishmentlabs.com/. An archived version of
the webcast will be available on the same website following
completion of the event.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology
company dedicated to improving women’s health and wellness through
the power of science, engineering, and technology. The Company
offers a portfolio of Femtech solutions for breast health, breast
aesthetics and breast reconstruction. The over three million
Motiva® devices Establishment Labs has delivered to plastic and
reconstructive surgeons since 2010 have created a new standard for
safety and patient satisfaction in the over 85 countries in which
they are available. The Motiva Flora® tissue expander is used to
improve outcomes in breast reconstruction following breast cancer
and it is the only regulatory-approved expander in the world with
an integrated port using radio-frequency technology that is MRI
conditional. Mia Femtech™, Establishment Lab’s unique minimally
invasive experience for breast harmony, is the Company’s most
recent breakthrough innovation. These solutions are supported by
over 200 patent applications in 25 separate patent families
worldwide and over 50 scientific studies and publications in peer
reviewed journals. Establishment Labs manufactures at two
facilities in Costa Rica compliant with all applicable regulatory
standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP
program. In 2018, the Company received an investigational device
exemption (IDE) from the FDA for Motiva Implants® and began a
clinical trial to support regulatory approval in the United States.
Please visit our website for additional information at
www.establishmentlabs.com.
Establishment Labs' Motiva silicone gel-filled implants are
currently not approved for commercial distribution in the United
States. The Company’s implants are undergoing PMA clinical
investigation pursuant to U.S. FDA regulations for investigational
medical devices.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231228914798/en/
Investor/Media Contact: Raj Denhoy 415-828-1044
rdenhoy@establishmentlabs.com
Establishment Labs (NASDAQ:ESTA)
Historical Stock Chart
From Apr 2024 to May 2024
Establishment Labs (NASDAQ:ESTA)
Historical Stock Chart
From May 2023 to May 2024